scholarly journals Prostate Cancer: How Young is too Young?

2015 ◽  
Vol 9 (4) ◽  
pp. 212-215 ◽  
Author(s):  
Sahil Gupta ◽  
Arjun Gupta ◽  
Ashish K. Saini ◽  
Kaustav Majumder ◽  
Kalpana Sinha ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Onset ◽  
The Elderly ◽  
Current Data ◽  
Distinct Phenotype ◽  
Cutaneous Malignancy ◽  
Urinary Tract Symptoms ◽  
The Usa ◽  
Prevalent Screening ◽  
Lower Urinary

Prostate cancer is the most common non-cutaneous malignancy in men. It is generally considered a cancer of the elderly, and the median age of presentation is 68 years. However 10% of new diagnoses in the USA occur in men aged ≤ 55 years. This may be due to more prevalent screening nowadays, and may also reflect the diagnosis of an increasingly recognized but underappreciated entity, i.e. early-onset prostate cancer. Patients with early onset prostate cancer pose unique challenges. Current data suggest that early-onset prostate cancer is a distinct phenotype—from both an etiological and clinical perspective— that deserves further attention. We present a case of a 28-year-old man who presented with lower urinary tract symptoms and was diagnosed with advanced stage prostate cancer.

Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder

2021 ◽  
Vol 14 (1) ◽  
pp. 53-57
Author(s):  
Tomasz Wiatr ◽  
Piotr Chłosta
Keyword(s):  
Elderly People ◽  
The Elderly ◽  
Similar Efficacy ◽  
Urgency Incontinence ◽  
Bladder Training ◽  
Adrenoceptor Agonist ◽  
Urinary Tract Symptoms ◽  
M3 Receptors ◽  
Lower Urinary

Lower urinary tract symptoms, including urgency, urgency incontinence, pollakiuria and nocturia are common in the elderly people and has significant impact on quality of life. Pharmacological treatment is recommended when conservative management, such as fluid intake normalization or bladder training, does not alleviate symptoms. Antimuscarinics were often used as the I line treatment for OAB, as these drugs block the activity of the muscarinic M2/M3 receptors in the bladder and provide a significant clinical benefit for OAB symptoms in the elderly people, but their side effects are common, often leading to treatment discontinuation. Mirabegron, a β3-adrenoceptor agonist, shows similar efficacy to antimuscarinic drugs without the risk of anticholinergic effects.

Efficacy of tadalafil against lower urinary tract symptoms after low-dose-rate brachytherapy in prostate cancer patients

2018 ◽  
Vol 12 (3) ◽  
pp. 223-227
Author(s):  
T Saito ◽  
T Minagawa ◽  
T Ogawa ◽  
O Ishizuka
Keyword(s):  
Prostate Cancer ◽  
Urinary Tract ◽  
Dose Rate ◽  
Cancer Patients ◽  
Lower Urinary Tract ◽  
Low Dose ◽  
Low Dose Rate ◽  
Urinary Tract Symptoms ◽  
Low Dose Rate Brachytherapy ◽  
Lower Urinary

Objectives: This study was performed to evaluate the effects of addition of tadalafil to tamsulosin in the treatment of brachytherapy patients with lower urinary tract symptoms (LUTS). Methods: Localized prostate cancer patients who developed LUTS after low-dose-rate brachytherapy (LDR-BT) were first treated with alpha-1 blockers (tamsulosin, 0.2 mg per day). Those still suffering from LUTS were additionally treated with phosphodiesterase type 5 inhibitor (tadalafil, 5 mg/day). LUTS was evaluated by the International Prostate Symptom Score (IPSS), IPSS Quality of Life (QOL) score, Overactive Bladder Symptom Score (OABSS), and the International Index of Erectile Function 5 (IIEF5) score before brachytherapy, before treatment with tadalafil, and after three months of treatment with tadalafil. Results: Twenty-three patients were enrolled in the study. Each subscore of the IPSS (storage symptom, voiding symptom, and postvoiding symptom) and the QOL score improved, but OABSS and IIEF5 did not show significant recovery after addition of tadalafil treatment. When patient characteristics and each question score were surveyed, time from seed implantation until treatment with tadalafil showed the strongest correlation with recovery. Conclusions: Addition of tadalafil to tamsulosin treatment was effective against LUTS in localised prostate cancer patients after brachytherapy. Evidence level: 2b

scholarly journals The Effect of Benign Lower Urinary Tract Symptoms on Subsequent Prostate Cancer Testing and Diagnosis

2013 ◽  
Vol 63 (6) ◽  
pp. 1021-1027 ◽  
Author(s):  
Christopher J. Weight ◽  
Simon P. Kim ◽  
Debra J. Jacobson ◽  
Michaela E. McGree ◽  
Stephen A. Boorjian ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urinary Tract Symptoms ◽  
Lower Urinary
Sign in / Sign up

Export Citation Format

Share Document